Detalhe da pesquisa
1.
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
Acta Pharmacol Sin
; 45(6): 1264-1275, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438582